| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3402858 | Enfermedades Infecciosas y Microbiología Clínica | 2008 | 8 Pages |
Abstract
This article reviews aspects related to nosocomial pneumonia due to Gram-positive microorganisms and especially episodes due to MRSA, because of their growing incidence and poor prognosis. The available therapeutic options, their suitability, and the emergent therapeutic options that aim to improve prognosis in patients with this kind of infection are evaluated. Given the lack of effective alternatives to treat nosocomial pneumonia due to MRSA, the possibility of using linezolid as the best available strategy to date is discussed.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
Thiago Lisboa, Jordi Rello,